Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.935 USD | +0.78% | -3.73% | -17.66% |
May. 09 | Transcript : Xeris Biopharma Holdings, Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | Earnings Flash (XERS) XERIS BIOPHARMA HOLDINGS Reports Q1 Revenue $40.6M, vs. Street Est of $41.8M | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-17.66% | 285M | C | ||
+39.22% | 727B | C+ | ||
+30.57% | 592B | B | ||
-7.85% | 347B | C+ | ||
+15.48% | 319B | B- | ||
-0.12% | 274B | C+ | ||
+12.55% | 238B | B+ | ||
+6.65% | 204B | B- | ||
-6.09% | 203B | A+ | ||
-3.37% | 160B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- XERS Stock
- Ratings Xeris Biopharma Holdings, Inc.